Latest Industry Insights
“Rewriting the Textbook” for Precision Medicine
Technology Networks recently had the pleasure of speaking with Mark Fidock, vice president for Diagnostic Development, Precision Medicine at AstraZeneca, to find out how the company is “rising to the challenge” of delivering precision medicines for chronic diseases.
Meet the Scientists Bringing Back the Extinct Tasmanian Tiger
The biotech/genetic engineering company Colossal – co-founded in 2021 by renowned geneticist Professor George Church and serial entrepreneur Ben Lamm – announced it has begun a de-extinction project of the thylacine – an Australian marsupial commonly referred to as the “Tasmanian tiger”. Technology Networks interviewed the team to learn more.
Broadening the Adoption of Pharmacogenomic Testing
Technology Networks recently had the pleasure of speaking to Dr. Philip Empey, to learn more about the Pharmacogenomics Center for Excellence and how it is working to prove the clinical utility of predictive PGx testing.
Exploring Flow Electroporation for Cell Engineering
Technology Networks spoke to Dr. Cenk Sumen, chief scientific officer of MaxCyte, about their pioneering cell engineering platform.
Combining Coding and Biology To Engineer Human Cells
To learn more about new technologies being developed for drug discovery and cell therapy, Technology Networks spoke to bit.bio's Dr. Farah Patell-Socha and Furqan Iqbal.
What’s Hot in Synthetic Biology Right Now?
In this opinion piece, Eric Rhodes, CEO of ERS Genomics, shares his roundup of some of the most exciting innovations in synthetic biology right now.
Using Machine Learning To Enhance Biomarkers for Cancer Immunotherapy
In this interview, we spoke to Rachel Marty Pyke PhD, manager of bioinformatics science at Personalis, to find out how machine learning can be used to detect genomic instability as a biomarker for cancer immunotherapy.
Bridging the Gap Between In Vitro and Animal Models of Liver Disease
We spoke to Dr. Audrey Dubourg, product manager at CN Bio to find out more about how its organ-on-chip platform could bridge the gap between the current 2D models and animal models, providing human-relevant insights into diseases such as non-alcoholic steatohepatitis.
Advancing Synthetic Biology With Automation
In this piece, Adam Clore explores how smart automation can help synthetic biology companies become more resilient.
The Impact of Funding on Longevity Research
To find out more about how early-stage funding could improve longevity research, we had the pleasure of speaking to Garri Zmudze, executive director of the Longevity Science Foundation.